Details of Disease

General Information of Disease (ID: DISBBTY5)

Disease Name Refractory hematologic malignancy
Synonyms refractory hematologic malignancy; refractory hematologic cancer
Disease Class 2A85: Mature B-cell lymphoma
Definition A hematologic malignancy that is resistant to treatment.
Disease Hierarchy
DISNCK1H: Haematopoietic/lymphoid cancer
DISCDP7W: Haematological malignancy
DISBBTY5: Refractory hematologic malignancy
ICD Code
ICD-11
ICD-11: 2A85.5
ICD-10
ICD-10: C83.1
Disease Identifiers
MONDO ID
MONDO_0004111
UMLS CUI
C1335724
MedGen ID
233400

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
INCB054329 DM7TZL0 Phase 1/2 Small molecular drug [1]
ProTmune DMZ6TF1 Phase 1/2 Cell therapy [2]
Alvespimycin hydrochloride DM6KU93 Phase 1 Small molecular drug [3]
AMG 397 DM7CNTG Phase 1 Small molecular drug [4]
PRGN-3005 DMCUE71 Phase 1 CAR T Cell Therapy [5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 ClinicalTrials.gov (NCT02431260) An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02743351) Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT03465540) Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT03907527) Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.